TY - JOUR
T1 - VP 16-213 and cytosine-arabinoside combination chemotherapy for refractory acute lymphoblastic leukemia in adults
AU - Morra, E.
AU - Lazzarino, M.
AU - Alessandrino, E. P.
AU - Inverardi, D.
AU - Canevari, A.
AU - Bernasconi, C.
PY - 1984
Y1 - 1984
N2 - Fifteen adult patients with refractory or relapsing acute lymphoblastic leukemia (ALL) received a 5-day remission induction regimen consisting of VP 16-213 (60 mg/m2 every 12 hr) and cytosine-arabinoside (100 mg/m2 every 12 hr) up to a maximum of three courses. The overall response rate was 60% ( 9 15), four patients (27%) achieving CR and five (33%) attaining PR. Responders were maintained with monthly courses of the same combination until progressive disease developed. The median duration of response was 4.5 months (2-12+ months). The regimen was relatively well tolerated. The major toxicity was hematologic. Non-hematologic toxicities included mild nausea and vomiting ( 11 15) and total alopecia ( 15 15). The results obtained with this combination are encouraging, in view of the poor prognosis associated with refractory or relapsing ALL in adults.
AB - Fifteen adult patients with refractory or relapsing acute lymphoblastic leukemia (ALL) received a 5-day remission induction regimen consisting of VP 16-213 (60 mg/m2 every 12 hr) and cytosine-arabinoside (100 mg/m2 every 12 hr) up to a maximum of three courses. The overall response rate was 60% ( 9 15), four patients (27%) achieving CR and five (33%) attaining PR. Responders were maintained with monthly courses of the same combination until progressive disease developed. The median duration of response was 4.5 months (2-12+ months). The regimen was relatively well tolerated. The major toxicity was hematologic. Non-hematologic toxicities included mild nausea and vomiting ( 11 15) and total alopecia ( 15 15). The results obtained with this combination are encouraging, in view of the poor prognosis associated with refractory or relapsing ALL in adults.
UR - http://www.scopus.com/inward/record.url?scp=0021750053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021750053&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(84)90138-X
DO - 10.1016/0277-5379(84)90138-X
M3 - Article
C2 - 6594241
AN - SCOPUS:0021750053
VL - 20
SP - 1471
EP - 1475
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 12
ER -